• Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub
  •  0 items - £0.00
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to footer

Before Header

  • My account
  •  0 items - £0.00

Action Duchenne

Header Right

  • Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub

News

You are here: Home / News

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

15 February 2024 by John Marrin

On February 13th, Edgewise Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for …

<strong>Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)</strong>Read More

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

31 January 2024 by John Marrin

On the Monday the 29th of January, Sarepta Therapeutics announced positive data from Part B of the MOMENTUM study. The MOMENTUM Study is a global …

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51Read More

The European Medicines Agency confirms recommendation for non-renewal of authorisation in the EU of Duchenne muscular dystrophy medicine Translarna

27 January 2024 by Lizzie Cox

We shared challenging news with the Duchenne community in September 2023. The European Medicine Agency's (EMA) human medicines committee (CHMP) …

The European Medicines Agency confirms recommendation for non-renewal of authorisation in the EU of Duchenne muscular dystrophy medicine TranslarnaRead More

Dyne Therapeutics Announces Positive Initial Clinical Data From DELIVER Trials in DMD Patients

11 January 2024 by John Marrin

Dyne Therapeutics have reported their initial clinical data from the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are …

Dyne Therapeutics Announces Positive Initial Clinical Data From DELIVER Trials in DMD PatientsRead More

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

11 January 2024 by John Marrin

PepGen Inc., a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies, today announced that the first patient …

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingRead More

Wave Life Sciences Announce the Start of the FORWARD-53 Clinical Study 

21 December 2023 by John Marrin

Wave Life Sciences Announce the Start of the FORWARD-53 Clinical Study  On the 15th of December 2023, Wave Life Sciences announced the initiation …

<strong>Wave Life Sciences Announce the Start of the FORWARD-53 Clinical Study </strong>Read More

PTC Therapeutics Provides Updates on Translarna™ (ataluren) regulatory activities in Europe and the United States

10 December 2023 by Lizzie Cox

PTC Therapeutics has announced, on the 5th of December 2023, an update on their regulatory progress with the European Medicines Association (EMA) and …

<strong>PTC Therapeutics Provides Updates on </strong><strong>Translarna™ (ataluren) regulatory activities in Europe and the United States</strong>Read More

FDA Grants Edgewise Therapeutics Inc Orphan Drug and Rare Paediatric Disease Designations for Its Muscular Dystrophy Program.

9 December 2023 by Lizzie Cox

On the 30th November Edgewise Therapeutics Inc. (a leading muscle disease biopharmaceutical company) announced that the U.S. Food & Drug …

FDA Grants Edgewise Therapeutics Inc Orphan Drug and Rare Paediatric Disease Designations for Its Muscular Dystrophy Program.Read More

United Nations Officially Designates September 7th as World Duchenne Awareness Day

1 December 2023 by Lizzie Cox

The global rare disease community is celebrating the UN’s first formal acknowledgement of a day dedicated to a rare disease. In a groundbreaking …

<strong>United Nations Officially Designates September 7th as World Duchenne Awareness Day</strong>Read More

Solid Biosciences Receives FDA Clearance for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

16 November 2023 by Lizzie Cox

Solid Biosciences Receives FDA Clearance for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 Solid Biosciences Inc., a leading life …

Solid Biosciences Receives FDA Clearance for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003Read More

Stakes ‘couldn’t be higher’ – PTC CEO on propect of Translarna losing EU conditional authorisation

16 November 2023 by Lizzie Cox

Stakes 'couldn't be higher' – PTC CEO on prospect of Translarna losing EU conditional authorisation PTC Therapeutics' Translarna, a critical …

Stakes ‘couldn’t be higher’ – PTC CEO on propect of Translarna losing EU conditional authorisationRead More

Thank you for attending the Action Duchenne Annual International Conference 2023!

14 November 2023 by Lizzie Cox

…

Thank you for attending the Action Duchenne Annual International Conference 2023!Read More

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Interim pages omitted …
  • Page 49
  • Go to Next Page »

Footer

Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA

0300 102 1762
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

Site Footer

Fundraising Regulator badge with validation link

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852